Product news

Share this article:

The FDA has approved  Ixempra (ixabepilone), a new anti-cancer treatment, for use in patients with metastatic or locally advanced breast cancer who have not responded to certain other cancer drugs. The FDA evaluated Ixempra under priority review, completing its assessment of the drug's safety and effectiveness in six months. Ixempra is administered by intravenous infusion. It is distributed by Bristol-Myers Squibb.

Sun Pharmaceutical said the FDA has approved its application to market its generic version of Novartis' Exelon (rivastigmine tartrate) capsules, used to treat mild to moderate dementia of Alzheimer's and Parkinson's disease. The India-based company said it shares a 180-day marketing exclusivity and in view of ongoing litigation with Novartis is evaluating launch options.

Novartis' Voltaren (diclofenac sodium topical gel) 1% received FDA approval as the first Rx topical treatment for pain associated with osteoarthritis.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.